SCHEDULE 13G/A: BlackRock Discloses 5.5% Stake in Edgewise Therapeutics
Beneficial Ownership Disclosure
BlackRock, Inc. has filed an amended Schedule 13G, disclosing a 5.5% beneficial ownership stake in Edgewise Therapeutics Inc., totaling 5,824,866 common shares.
Summary
- BlackRock, Inc. reported beneficial ownership of 5,824,866 common shares of EDGEWISE THERAPEUTICS INC.
- This ownership represents 5.5% of the total outstanding common stock of EDGEWISE THERAPEUTICS INC.
- BlackRock holds sole voting power over 5,717,579 shares and sole dispositive power over 5,824,866 shares.
- The filing is an Amendment No. 1 to a Schedule 13G, indicating an update to a previously filed statement.
- The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing disclosing beneficial ownership and does not contain information that would significantly alter sentiment, as it is a passive investment disclosure.
Positives
- A significant stake held by a major institutional investor like BlackRock may indicate confidence in the company's long-term prospects.
Future Outlook
No forward-looking statements or guidance from Edgewise Therapeutics Inc. are provided in this beneficial ownership disclosure.
Management Comments
- The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.
Industry Context
This filing represents a routine disclosure of institutional ownership by a major asset manager, BlackRock, in a publicly traded biotechnology company, Edgewise Therapeutics. It reflects BlackRock's ongoing portfolio management activities and its presence as a significant investor across various sectors.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Authorized Signatory for SEC Filings | Previous individuals under Power of Attorney dated April 30, 2023 | Eric Andruczyk, Richard Cundiff, R. Andrew Dickson, III, Spencer Fleming, Laura Hildner, David Maryles, Christopher Meade, Charles Park, James Raby, Daniel Riemer, David Rothenberg, Brenda Schulz | 2025-01-21 | New Power of Attorney issued, revoking previous one. |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Power of Attorney Update | BlackRock, Inc. issued a new Power of Attorney, effective January 21, 2025, authorizing specific individuals to execute SEC filings on its behalf and on behalf of its subsidiaries and affiliates. This new Power of Attorney revokes the previous one dated April 30, 2023. | 2025-01-21 | Streamlines the process for BlackRock's authorized personnel to comply with ownership and control-person reporting requirements. |
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional investor's stake, potentially signaling confidence.
- Management: Awareness of a large, passive institutional holder in the company's stock.
Key Dates
| Date | Description |
|---|---|
| 2023-04-30 | Previous Power of Attorney revoked by BlackRock, Inc. |
| 2025-01-21 | Effective date of the new Power of Attorney issued by BlackRock, Inc. |
| 2025-06-30 | Date of event which requires the filing of this statement. |
| 2025-07-17 | Signature date of the Schedule 13G filing by BlackRock, Inc. |
Keywords
Edgewise Therapeutics, BlackRock, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investment, SEC Filing, EWTI
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.